Tuberculosis Drug Resistance in an Area of Low Endemicity in 2004 to 2006: Semiquantitative Drug Susceptibility Testing and Genotyping-Reference-Cited by-同舟云学术

Tuberculosis Drug Resistance in an Area of Low Endemicity in 2004 to 2006: Semiquantitative Drug Susceptibility Testing and Genotyping

Published:2008-12 Issue:12 Volume:46 Page:4064-4067
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Springer Burkhard¹²³,Calligaris-Maibach Romana C.¹²,Ritter Claudia¹²,Böttger Erik C.¹²

Affiliation:

1. Institut für Medizinische Mikrobiologie, Universität Zürich, Zürich CH-8006, Switzerland

2. Nationales Zentrum für Mykobakterien, Zürich CH-8006, Switzerland

3. Institut für Medizinische Mikrobiologie und Hygiene, Österreichische Agentur für Gesundheit und Ernährungssicherheit, Graz A-8010, Austria

Abstract

ABSTRACT We determined the quantitative levels and the genetic mechanisms of resistance in drug-resistant clinical isolates of Mycobacterium tuberculosis sampled over a period of 3 years ( n = 45; 17 of the isolate were multidrug resistant). Our results led us to hypothesize that some strains categorized as resistant to isoniazid, ethambutol, or streptomycin by standard laboratory procedures of in vitro drug susceptibility testing may still respond to a treatment regimen that includes these agents.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.01114-08

Reference20 articles.

1. Böttger, E. C. 2001. Drug-resistant tuberculosis. Lancet357:1288-1289.

2. Fitness of antibiotic-resistant microorganisms and compensatory mutations

3. Böttger, E. C., and B. Springer. 2008. Tuberculosis: drug resistance, fitness, and strategies for global control. Eur. J. Pediatr.67:141-148.

4. CDC. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep.55:301-305.

5. High-Dose Isoniazid Therapy for Isoniazid-Resistant Murine Mycobacterium tuberculosis Infection

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of the effectiveness of molecular genetic and bacteriological methods in determining heteroresistance Mycobacterium tuberculosis to rifampicin;Tuberculosis and socially significant diseases;2022-11-16

2. Correlating genetic mutations with isoniazid phenotypic levels of resistance in Mycobacterium tuberculosis isolates from patients with drug-resistant tuberculosis in a high burden setting;European Journal of Clinical Microbiology & Infectious Diseases;2021-07-23

3. Identifying isoniazid resistance markers to guide inclusion of high-dose isoniazid in tuberculosis treatment regimens;Clinical Microbiology and Infection;2020-10

4. Improved Outcomes With High-dose Isoniazid in Multidrug-resistant Tuberculosis Treatment in Haiti;Clinical Infectious Diseases;2019-01-29

5. Analysis of isoniazid and rifampicin resistance in Mycobacterium tuberculosis isolates in Morocco using GenoType® MTBDRplus assay;Journal of Global Antimicrobial Resistance;2018-03